Following oral absorption and systemic distribution, apixaban reaches peak plasma concentrations within roughly 1–2 hours after dosing, a pharmacokinetic profile that supports timely inhibition of circulating factor Xa. Apixaban is rapidly absorbed after oral administration, with a time to peak plasma concentration (Tmax) of 1–2 h. Consistent with a relatively constrained distribution, apixaban shows a low steady-state volume of distribution across species, indicating that a substantial fraction of drug remains in the vascular compartment. The steady-state volume of distribution for apixaban is low in rats, dogs, and humans (approximately 0.31 L/kg). Serum protein binding is high in preclinical species (92–96% in rats and dogs), while being lower in humans; this binding profile shapes the free fraction available to inhibit factor Xa. Serum protein binding of apixaban is 92–96% in rats and dogs and lower in humans, monkey, and rabbit plasma. Apixaban is metabolized and transported through pathways involving CYP3A4/5 and efflux transporters. Apixaban is a substrate for CYP3A4/5, BCRP, and P-gp. Clinically relevant exposure is therefore modulated by drug–drug interactions: co-administration of strong CYP3A4/5 and P-gp inhibitors such as ketoconazole increases exposure approximately twofold, whereas strong inducers such as rifampin decrease exposure by about 50%. Co-administration of strong inhibitors of CYP3A4/5 and P-gp (ketoconazole) increases apixaban exposure approximately twofold, while co-administration with strong inducers (rifampin) decreases apixaban exposure by approximately 50%. Unchanged apixaban dominates the pharmacologic effect because the predominant circulating metabolite, O-demethyl apixaban sulfate, is inactive against human FXa.

At the primary molecular target level, apixaban directly inhibits activated factor X (FXa) as a reversible active-site inhibitor. Apixaban is a highly potent, reversible, active-site inhibitor of human FXa. In a tripeptide substrate assay, apixaban inhibits FXa with a Ki of 0.08 nM at 25°C and 0.25 nM at 37°C, demonstrating extraordinarily high potency under physiologically relevant temperatures. Apixaban is a competitive inhibitor of FXa versus the synthetic tripeptide substrate, confirming that inhibition is driven by binding in the active site. Structural analyses localize the pharmacophore to two FXa pockets: the p-methoxyphenyl P1 moiety deeply inserted into the S1 pocket and the aryllactam P4 moiety stacked in the hydrophobic S4 pocket, together explaining apixaban's simultaneous potency and selectivity.

In the immediate downstream consequences domain, apixaban inhibition blocks FXa catalytic action within the prothrombinase complex. In a prothrombinase assay, apixaban blocks FXa-mediated conversion of prothrombin with a Ki of 0.62 nM, and this translates into functional suppression of thrombin generation. Inhibition of FXa by apixaban reduces tissue factor–initiated thrombin generation in human platelet-poor plasma in vitro, reflected by an IC50 for the rate of thrombin generation of 50 nM and an IC50 for attenuation of peak thrombin concentration of 100 nM. In platelet-rich conditions that better approximate thrombus biology, apixaban reduces tissue factor–induced thrombin generation with an IC50 of 37 nM. Consistent with reduced thrombin output, apixaban also indirectly inhibits platelet aggregation induced by thrombin derived from tissue factor–mediated coagulation.

At the coagulation cascade level, reduced FXa activity diminishes fibrin generation and thrombus propagation. In flow studies, apixaban at therapeutic concentration reduced thrombus formation, fibrin association, and platelet-aggregate formation, consistent with the drug's strategy to specifically target activated FXa in the blood coagulation cascade.

Regarding selectivity and kinetic properties, apixaban maintains greater than 30,000-fold selectivity for FXa over other human coagulation proteases. Kinetically, apixaban shows a rapid onset of FXa inhibition with an association rate constant of approximately 20 µM⁻¹/s, and demonstrates reversibility as FXa activity recovers after dilution of a pre-formed complex, confirming recovery of FXa activity at 37°C after 200-fold dilution of a pre-formed FXa:apixaban complex into tripeptide substrate.

In clinical translation, anti-FXa activity tracks plasma concentration closely, peaking at times of apixaban peak plasma concentrations, and the pharmacodynamic effect of apixaban is closely correlated with apixaban plasma concentration. Apixaban has an apparent elimination half-life of 12 hours and its anticoagulant effect lasts for 24 hours after the last dose is given. In routine coagulation testing, apixaban prolongs clotting times in normal human plasma assays including aPTT, PT, modified PT (mPT), and HepTest; mPT and HepTest appear to be 10–20 times more sensitive than aPTT and PT for monitoring apixaban's anticoagulant effect in vitro.